Abbvie and Google’s Calico extend age-related disease partnership to $2.5bn

pharmafile | June 27, 2018 | News story | Research and Development, Sales and Marketing AbbVie, Cancer, Goggle, calico, pharma 

The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development collaboration, originally signed in 2014, for another three years.

The $1.5 billion partnership has proven so successful that both Abbvie and Calico are to inject an additional $500 million each, with the latter responsible for research and early development until 2022 and pushing collaboration projects through Phase 2a until 2027. Abbvie will support Calico in these pursuits, and will be able to assume late-stage development and commercialisation in those candidates that make it past Phase 2a.

The project focuses on the development of interventions for age-related disease, including neurodegenerative conditions and cancer.

“We’ve built a successful collaboration – both scientifically and culturally – that is advancing cutting-edge science,” said Dr Michael Severino, Executive Vice President, Research and Development, Chief Scientific Officer, at AbbVie. “Calico has attracted an outstanding team of world-class scientists and the extension of this collaboration allows us to further build on the research we’ve done to identify transformative treatment options for patients with age-related diseases.”

Calico Chief Executive and former Genetech Chairman Dr Arthur D Levinson added: “Our collaboration with AbbVie has fully met our high expectations. Our initial agreement created a unique partnership and this extension will accelerate further our efforts to understand the science of aging to advance novel therapies for patients.”

Matt Fellows

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to …

Latest content